Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
chidaniline
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
Chidaniline is an investigational drug referenced in recent clinical trials as part of combination regimens for the treatment of acute myeloid leukemia (AML), particularly in elderly, untreated patients. It is being studied alongside venetoclax and azacitidine, followed by decitabine and a MAG regimen. The precise chemical structure, mechanism of action, and pharmacological class of chidaniline are not publicly disclosed in available literature or regulatory databases as of June 2025. Its inclusion in AML trials suggests it may have antineoplastic or targeted therapy properties, but further details remain unavailable from current sources[2][3][7][9].
Beyond the preview
Go deeper on chidaniline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on chidaniline.